廣生堂(300436.SZ):新冠藥GST-HG171完成關鍵性註冊臨牀試驗計劃病例數入組
格隆匯5月4日丨廣生堂(300436.SZ)公佈,創新藥控股子公司福建廣生中霖生物科技有限公司的口服小分子3CL蛋白酶抑制劑一類創新藥物泰阿特韋GST-HG171片,其評估泰中定在輕型/中型新型冠狀病毒感染患者中的多中心、隨機、雙盲、安慰劑對照的有效性和安全性的II/III期關鍵性註冊臨牀研究,已按照臨牀方案要求完成了計劃病例數1200例的新冠感染患者入組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.